{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T00:28:15Z","timestamp":1791332895810,"version":"4.3.1"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"7577","license":[{"start":{"date-parts":[[2015,11,1]],"date-time":"2015-11-01T00:00:00Z","timestamp":1446336000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nature"],"published-print":{"date-parts":[[2015,11]]},"DOI":"10.1038\/nature15711","type":"journal-article","created":{"date-parts":[[2015,11,4]],"date-time":"2015-11-04T14:37:33Z","timestamp":1446647853000},"page":"245-248","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":49,"title":["Resensitizing daclatasvir-resistant hepatitis C variants by allosteric modulation of NS5A"],"prefix":"10.1038","volume":"527","author":[{"given":"Jin-Hua","family":"Sun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald R.","family":"O\u2019Boyle II","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert A.","family":"Fridell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David R.","family":"Langley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunfu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan B.","family":"Roberts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Nower","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin M.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederic","family":"Moulin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle J.","family":"Nophsker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying-Kai","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengping","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Rigat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Tu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piyasena","family":"Hewawasam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Kadow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas A.","family":"Meanwell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Cockett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie A.","family":"Lemm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Kramer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makonen","family":"Belema","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,11,4]]},"reference":[{"key":"BFnature15711_CR1","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1002\/hep.26141","volume":"57","author":"K Mohd Hanafiah","year":"2013","unstructured":"Mohd Hanafiah, K., Groeger, J., Flaxman, A. D. & Wiersma, S. T. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology 57, 1333\u20131342 (2013)","journal-title":"Hepatology"},{"key":"BFnature15711_CR2","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1016\/S1473-3099(05)70216-4","volume":"5","author":"CW Shepard","year":"2005","unstructured":"Shepard, C. W., Finelli, L. & Alter, M. J. Global epidemiology of hepatitis C virus infection. Lancet Infect. Dis. 5, 558\u2013567 (2005)","journal-title":"Lancet Infect. Dis."},{"key":"BFnature15711_CR3","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/j.jhep.2013.03.030","volume":"59","author":"JM Pawlotsky","year":"2013","unstructured":"Pawlotsky, J. M. NS5A inhibitors in the treatment of hepatitis C. J. Hepatol . 59, 375\u2013382 (2013)","journal-title":"J. Hepatol"},{"key":"BFnature15711_CR4","doi-asserted-by":"publisher","first-page":"3991","DOI":"10.1073\/pnas.1203110110","volume":"110","author":"J Guedj","year":"2013","unstructured":"Guedj, J. et al. Modeling shows that the NS5A inhibitor daclatasvir has two modes of action and yields a shorter estimate of the hepatitis C virus half-life. Proc. Natl Acad. Sci. USA 110, 3991\u20133996 (2013)","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnature15711_CR5","doi-asserted-by":"publisher","first-page":"2485","DOI":"10.1099\/vir.0.80204-0","volume":"85","author":"A Macdonald","year":"2004","unstructured":"Macdonald, A. & Harris, M. Hepatitis C virus NS5A: tales of a promiscuous protein. J. Gen. Virol. 85, 2485\u20132502 (2004)","journal-title":"J. Gen. Virol."},{"key":"BFnature15711_CR6","first-page":"267","volume":"Ch. 9","author":"Y He","year":"2006","unstructured":"He, Y., Staschke, K. A. & Tan, S.-L. in Hepatitis C Viruses Genomes and Molecular Biology (ed. Tan, S.-L. ) Ch. 9, 267\u2013291 (Horizon Bioscience, 2006)","journal-title":"Hepatitis C Viruses Genomes and Molecular Biology"},{"key":"BFnature15711_CR7","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1038\/nature03580","volume":"435","author":"TL Tellinghuisen","year":"2005","unstructured":"Tellinghuisen, T. L., Marcotrigiano, J. & Rice, C. M. Structure of the zinc-binding domain of an essential component of the hepatitis C virus replicase. Nature 435, 374\u2013379 (2005)","journal-title":"Nature"},{"key":"BFnature15711_CR8","doi-asserted-by":"publisher","first-page":"4395","DOI":"10.1128\/JVI.02352-08","volume":"83","author":"RA Love","year":"2009","unstructured":"Love, R. A., Brodsky, O., Hickey, M. J., Wells, P. A. & Cronin, C. N. Crystal structure of a novel dimeric form of NS5A domain I protein from hepatitis C virus. J. Virol. 83, 4395\u20134403 (2009)","journal-title":"J. Virol."},{"key":"BFnature15711_CR9","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1002\/pro.2456","volume":"23","author":"SM Lambert","year":"2014","unstructured":"Lambert, S. M. et al. The crystal structure of NS5A domain 1 from genotype 1a reveals new clues to the mechanism of action for dimeric HCV inhibitors. Protein Sci. 23, 723\u2013734 (2014)","journal-title":"Protein Sci."},{"key":"BFnature15711_CR10","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1038\/nature08960","volume":"465","author":"M Gao","year":"2010","unstructured":"Gao, M. et al. Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect. Nature 465, 96\u2013100 (2010)","journal-title":"Nature"},{"key":"BFnature15711_CR11","doi-asserted-by":"publisher","first-page":"13594","DOI":"10.1128\/JVI.79.21.13594-13605.2005","volume":"79","author":"D Quinkert","year":"2005","unstructured":"Quinkert, D., Bartenschlager, R. & Lohmann, V. Quantitative analysis of the hepatitis C virus replication complex. J. Virol. 79, 13594\u201313605 (2005)","journal-title":"J. Virol."},{"key":"BFnature15711_CR12","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.1128\/JVI.75.3.1252-1264.2001","volume":"75","author":"T Pietschmann","year":"2001","unstructured":"Pietschmann, T., Lohmann, V., Rutter, G., Kurpanek, K. & Bartenschlager, R. Characterization of cell lines carrying self-replicating hepatitis C virus RNAs. J. Virol. 75, 1252\u20131264 (2001)","journal-title":"J. Virol."},{"key":"BFnature15711_CR13","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/j.virol.2013.06.032","volume":"444","author":"DR O\u2019Boyle II","year":"2013","unstructured":"O\u2019Boyle, D. R. II et al. Characterizations of HCV NS5A replication complex inhibitors. Virology 444, 343\u2013354 (2013)","journal-title":"Virology"},{"key":"BFnature15711_CR14","doi-asserted-by":"publisher","first-page":"3641","DOI":"10.1128\/AAC.00556-10","volume":"54","author":"RA Fridell","year":"2010","unstructured":"Fridell, R. A., Qiu, D., Wang, C., Valera, L. & Gao, M. Resistance analysis of the hepatitis C virus NS5A inhibitor BMS-790052 in an in vitro replicon system. Antimicrob. Agents Chemother. 54, 3641\u20133650 (2010)","journal-title":"Antimicrob. Agents Chemother."},{"key":"BFnature15711_CR15","doi-asserted-by":"publisher","first-page":"5230","DOI":"10.1128\/AAC.01209-12","volume":"56","author":"LA Pelosi","year":"2012","unstructured":"Pelosi, L. A., Voss, S., Liu, M., Gao, M. & Lemm, J. A. Effect on hepatitis C virus replication of combinations of direct-acting antivirals, including NS5A inhibitor daclatasvir. Antimicrob. Agents Chemother. 56, 5230\u20135239 (2012)","journal-title":"Antimicrob. Agents Chemother."},{"key":"BFnature15711_CR16","unstructured":"Nettles, R. E. et al. BMS-824393 is a potent HCV NS5A inhibitor with substantial antiviral activity when given as monotherapy in subjects with chronic G1 HCV infection. 61th Ann. Meeting AASLD (2010)"},{"key":"BFnature15711_CR17","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/0092-8674(91)90615-6","volume":"66","author":"EP Sandgren","year":"1991","unstructured":"Sandgren, E. P. et al. Complete hepatic regeneration after somatic deletion of an albumin-plasminogen activator transgene. Cell 66, 245\u2013256 (1991)","journal-title":"Cell"},{"key":"BFnature15711_CR18","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.jcv.2012.12.020","volume":"57","author":"D Hernandez","year":"2013","unstructured":"Hernandez, D., Zhou, N., Ueland, J., Monikowski, A. & McPhee, F. Natural prevalence of NS5A polymorphisms in subjects infected with hepatitis C virus genotype 3 and their effects on the antiviral activity of NS5A inhibitors. J. Clin. Virol. 57, 13\u201318 (2013)","journal-title":"J. Clin. Virol."},{"key":"BFnature15711_CR19","doi-asserted-by":"publisher","first-page":"S491","DOI":"10.1016\/S0168-8278(13)61210-6","volume":"58","author":"JF McCarville","year":"2013","unstructured":"McCarville, J. F., Seifer, M., Standring, D. N., Mayers, D. L. & IDX-06A\u2013001 Investigator Team. Treatment-emergent variants following 3 days of monotherapy with IDX719, a potent, pan-genotypic NS5A inhibitor, in subjects infected with HCV genotypes 1\u20134. J. Hepatol . 58 (suppl. 1), S491\u2013S492 (2013)","journal-title":"J. Hepatol"},{"key":"BFnature15711_CR20","doi-asserted-by":"crossref","unstructured":"Everson, G. T. et al. Phase 2b study of the interferon-free and ribavirin-free combination of daclatasvir, asunaprevir, and BMS-791325 for 12 weeks in treatment-naive patients with chronic HCV genotype 1 infection. 64th Ann. Meeting AASLD (2013)","DOI":"10.1053\/j.gastro.2013.10.057"},{"key":"BFnature15711_CR21","doi-asserted-by":"publisher","first-page":"40835","DOI":"10.1074\/jbc.M404761200","volume":"279","author":"F Penin","year":"2004","unstructured":"Penin, F. et al. Structure and function of the membrane anchor domain of hepatitis C virus nonstructural protein 5A. J. Biol. Chem. 279, 40835\u201340843 (2004)","journal-title":"J. Biol. Chem."},{"key":"BFnature15711_CR22","unstructured":"Pack, S. K. et al. Hepatitis C virus inhibitors. US patent 9,006,455 B2 (2015)"},{"key":"BFnature15711_CR23","doi-asserted-by":"publisher","first-page":"1976","DOI":"10.1021\/jm301796k","volume":"57","author":"DR St. Laurent","year":"2014","unstructured":"St. Laurent, D. R. et al. HCV NS5A replication complex inhibitors. Part 4. Optimization for genotype 1a replicon inhibitory activity. J. Med. Chem. 57, 1976\u20131994 (2014)","journal-title":"J. Med. Chem."},{"key":"BFnature15711_CR24","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1016\/S0040-4020(01)82417-0","volume":"40","author":"D Seebach","year":"1984","unstructured":"Seebach, D., Naef, R. & Calderari, G. \u03b1-Alkylation of \u03b1-heterosubstituted carboxylic acids without racemization. Tetrahedron 40, 1313\u20131324 (1984)","journal-title":"Tetrahedron"},{"key":"BFnature15711_CR25","first-page":"3915","volume":"22","author":"R Nagase","year":"2006","unstructured":"Nagase, R., Oguni, Y., Misaki, T. & Tanabe, Y. Practical and robust method for the preparation of Seebach and Frater\u2019s chiral template, cis-2-substituted 5-methyl (or phenyl)-1,3-dioxolan-4-ones. Synthesis 22, 3915\u20133917 (2006)","journal-title":"Synthesis"},{"key":"BFnature15711_CR26","doi-asserted-by":"publisher","first-page":"3409","DOI":"10.1021\/jo200401a","volume":"76","author":"LR Reddy","year":"2011","unstructured":"Reddy, L. R., Gupta, A. P. & Liu, Y. Asymmetric synthesis of \u03b1-amino acids by reduction of N-tert-butanesulfinyl ketimine esters. J. Org. Chem. 76, 3409\u20133415 (2011)","journal-title":"J. Org. Chem."},{"key":"BFnature15711_CR27","doi-asserted-by":"publisher","first-page":"2033","DOI":"10.1021\/jm401499g","volume":"57","author":"JO Link","year":"2014","unstructured":"Link, J. O. et al. Discovery of ledipasvir (GS-5885): a potent, once-daily oral NS5A inhibitor for the treatment of hepatitis C virus infection. J. Med. Chem. 57, 2033\u20132046 (2014)","journal-title":"J. Med. Chem."},{"key":"BFnature15711_CR28","doi-asserted-by":"publisher","first-page":"e1001086","DOI":"10.1371\/journal.ppat.1001086","volume":"6","author":"CJ Baldick","year":"2010","unstructured":"Baldick, C. J. et al. A novel small molecule inhibitor of hepatitis C virus entry. PLoS Pathog. 6, e1001086 (2010)","journal-title":"PLoS Pathog."}],"container-title":["Nature"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/nature15711.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nature15711","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nature15711.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T17:46:38Z","timestamp":1684431998000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/nature15711"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,11]]},"references-count":28,"journal-issue":{"issue":"7577","published-print":{"date-parts":[[2015,11]]}},"alternative-id":["BFnature15711"],"URL":"https:\/\/doi.org\/10.1038\/nature15711","relation":{},"ISSN":["0028-0836","1476-4687"],"issn-type":[{"value":"0028-0836","type":"print"},{"value":"1476-4687","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,11]]},"assertion":[{"value":"19 March 2015","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 September 2015","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 November 2015","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors are or were, at the time this work was conducted, employees of Bristol-Myers Squibb, a company that markets antiviral therapies for the treatment of HCV.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}